Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RAS-mutant Colorectal Cancer”

46 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 46 results

Not applicableStudy completedNCT01822444
What this trial is testing

ANGIOPREDICT. ICORG 12-16, V3

Who this might be right for
Advanced Colorectal Cancer
Cancer Trials Ireland 76
Testing effectiveness (Phase 2)Ended earlyNCT05983367
What this trial is testing

Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

Who this might be right for
Colorectal CancerMetastatic Colon Cancer
Inspirna, Inc. 76
Testing effectiveness (Phase 2)UnknownNCT01190462
What this trial is testing

Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Leiden University Medical Center 51
Early research (Phase 1)Ended earlyNCT02933944
What this trial is testing

Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer

Who this might be right for
Rectal Cancer
Targovax ASA 6
Testing effectiveness (Phase 2)UnknownNCT06206096
What this trial is testing

PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC

Who this might be right for
Colorectal CancerRAS MutationColorectal Neoplasms+1 more
Chinese PLA General Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT06128551
What this trial is testing

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal CancerPancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 534
Testing effectiveness (Phase 2)Study completedNCT01927341
What this trial is testing

Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors

Who this might be right for
Metastatic Colorectal Cancer
Pfizer 53
Early research (Phase 1)Active Not RecruitingNCT05462717
What this trial is testing

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma+1 more
Revolution Medicines, Inc. 222
Testing effectiveness (Phase 2)UnknownNCT01110785
What this trial is testing

Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Leiden University Medical Center 46
Testing effectiveness (Phase 2)Study completedNCT03271047
What this trial is testing

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Who this might be right for
MSSRAS-mutant Colorectal Cancer
Pfizer 75
Not applicableStudy completedNCT03010722
What this trial is testing

Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy

Who this might be right for
Metastatic Colorectal Cancer
Royal Marsden NHS Foundation Trust 49
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07007728
What this trial is testing

Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

Who this might be right for
Colorectal NeoplasmsSecondary Malignant Neoplasm of Liver
Peking University Cancer Hospital & Institute 54
Early research (Phase 1)UnknownNCT04303403
What this trial is testing

Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma

Who this might be right for
Colorectal CancerPancreatic Adenocarcinoma
National Cancer Centre, Singapore 48
Post-approval studies (Phase 4)Study completedNCT01972490
What this trial is testing

Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases

Who this might be right for
Colorectal Neoplasms
Xu jianmin 241
Testing effectiveness (Phase 2)Ended earlyNCT01322815
What this trial is testing

A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI

Who this might be right for
Colon Cancer
Georgetown University 11
Large-scale testing (Phase 3)Active Not RecruitingNCT05171660
What this trial is testing

Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer Stage IV
Second Affiliated Hospital, School of Medicine, Zhejiang University 446
Early research (Phase 1)Study completedNCT02510001
What this trial is testing

MEK and MET Inhibition in Colorectal Cancer

Who this might be right for
Solid TumorColorectal Cancer
University of Oxford 82
Not applicableUnknownNCT04525313
What this trial is testing

The Prediction Model of Avastin Plus Chemotherapy in Unresectable Ras Mutant CRLM Patients

Who this might be right for
Colorectal CancerLiver Metastases
Fudan University 116
Early research (Phase 1)Study completedNCT03714958
What this trial is testing

Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type

Who this might be right for
Colorectal CancerAdvanced CancerMetastatic Cancer
Centre Leon Berard 12
Testing effectiveness (Phase 2)Ended earlyNCT04853043
What this trial is testing

Cetuximab in Third Line for Mutant APC, TP53 and RAS Patients With Refractory Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
University of Utah 7
Load More Results